AAAAAA
Results: 26-50/53
Authors:
Lamm, DL
Blumenstein, BA
Crissman, JD
Montie, JE
Gottesman, JE
Lowe, BA
Sarosdy, MF
Bohl, RD
Grossman, HB
Beck, TM
Leimert, JT
Crawford, ED
Citation: Dl. Lamm et al., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study, J UROL, 163(4), 2000, pp. 1124-1129
Authors:
Elias, L
Lew, D
Figlin, RA
Flanigan, RC
Thompson, ME
Triozzi, PL
Belt, RJ
Wood, DP
Rivkin, SE
Crawford, ED
Citation: L. Elias et al., Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study, CANCER, 89(3), 2000, pp. 597-603
Authors:
Crawford, ED
Batuello, JT
Snow, P
Gamito, EJ
McLeod, DG
Partin, AW
Stone, N
Montie, J
Stock, R
Lynch, J
Brandt, J
Citation: Ed. Crawford et al., The use of artificial intelligence technology to predict lymph node spreadin men with clinically localized prostate carcinoma, CANCER, 88(9), 2000, pp. 2105-2109
Authors:
Williamson, SK
Lew, D
Miller, GJ
Balcerzak, SP
Baker, LH
Crawford, ED
Citation: Sk. Williamson et al., Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma - A Southwest Oncology Group study, CANCER, 88(5), 2000, pp. 1159-1165
Authors:
Ziada, A
Rosenblum, M
Crawford, ED
Citation: A. Ziada et al., Hormonal therapy - Neoadjuvant, adjuvant, definitive, intermittent, CURR CLIN U, 2000, pp. 265-288
Authors:
Moinpour, CM
Troxel, A
Lovato, LC
Eisenberger, M
Blumenstein, BA
Crawford, ED
Citation: Cm. Moinpour et al., Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial - Response, J NAT CANC, 91(7), 1999, pp. 646-646
Authors:
Moinpour, CM
Troxel, A
Lovato, LC
Eisenberger, M
Blumenstein, BA
Crawford, ED
Citation: Cm. Moinpour et al., Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial - Response, J NAT CANC, 91(4), 1999, pp. 381-382
Authors:
Ziada, A
Grover, F
Crawford, ED
Citation: A. Ziada et al., The use of trans-oesophageal echocardiography in the management of intra-atrial thrombus in a patient with renal cell carcinoma, BJU INT, 84(6), 1999, pp. 737-738
Authors:
Sarosdy, MF
Schellhammer, PF
Soloway, MS
Vogelzang, NJ
Crawford, ED
Presti, J
Chodak, GW
Mitchell, P
Porter, L
Citation: Mf. Sarosdy et al., Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer, BJU INT, 83(7), 1999, pp. 801-806
Authors:
Goktas, S
Ziada, A
Crawford, ED
Citation: S. Goktas et al., Combined androgen blockade for advanced prostatic carcinoma, PROSTATE C, 2(4), 1999, pp. 172-179
Authors:
Ziada, AM
Crawford, ED
Citation: Am. Ziada et Ed. Crawford, Advanced prostate cancer, PROSTATE C, 2, 1999, pp. 21-26
Authors:
Kelloff, GJ
Lieberman, R
Brawer, MK
Crawford, ED
Labrie, F
Miller, GJ
Citation: Gj. Kelloff et al., Strategies for chemoprevention of prostate cancer, PROSTATE C, 2, 1999, pp. 27-33
Authors:
Lisle, TC
Ziada, AM
Andros, EA
Crawford, ED
Citation: Tc. Lisle et al., Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate andincidence of biochemical recurrence, MOL UROL, 3(3), 1999, pp. 263-268
Authors:
Alexander, FE
Andriole, GL
Aus, G
Auvinen, A
Beensterboer, P
Blijenberg, BG
Bonardi, R
Buys, S
Candas, B
Ciatto, S
Crawford, ED
Demers, R
de Koning, HJ
Denis, L
Dijk, MA
Figueiredo, F
Gellman, EP
Gohagan, J
Hakama, M
Hugosson, J
Kirkels, WI
Kranse, R
van der Kwast, TH
Lilja, H
Maattanen, L
Mandel, J
Miller, AB
Monteiro, H
Nelen, V
Oberman, A
Paez, A
Prorok, PC
Reding, D
Rietbergen, JWBW
Rose, DB
Sanchez, AB
Schroder, FH
da Silva, EC
Simpson, N
Smith, PH
Stadaert, B
Stenman, UH
Teppo, L
Turkes, A
Weissfeld, JL
Yokochi, L
Citation: Fe. Alexander et al., Rationale for randomised trials of prostate cancer screening, EUR J CANC, 35(2), 1999, pp. 262-271
Authors:
Crawford, ED
Citation: Ed. Crawford, The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials, EUR UROL, 35(5-6), 1999, pp. 511-514
Authors:
Crawford, ED
Leewansangtong, S
Goktas, S
Holthaus, K
Baier, M
Citation: Ed. Crawford et al., Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff forabnormal values, PROSTATE, 38(4), 1999, pp. 296-302
Authors:
Goktas, S
Crawford, ED
Citation: S. Goktas et Ed. Crawford, Optimal hormonal therapy for advanced prostatic carcinoma, SEMIN ONCOL, 26(2), 1999, pp. 162-173
Authors:
Crawford, ED
Rosenblum, M
Ziada, AM
Lange, PH
Citation: Ed. Crawford et al., Overview: Hormone refractory prostate cancer, UROLOGY, 54(6A), 1999, pp. 1-7
Authors:
Crawford, ED
Citation: Ed. Crawford, Summary: The role of the urologist in chemotherapy of hormone refractory prostate cancer, UROLOGY, 54(6A), 1999, pp. 51-52
Authors:
Ziada, A
Rosenblum, M
Crawford, ED
Citation: A. Ziada et al., Benign prostatic hyperplasia: An overview, UROLOGY, 53(3), 1999, pp. 1-6
Authors:
Crawford, ED
Lesser, AJ
Citation: Ed. Crawford et Aj. Lesser, Brittle to ductile: Fracture toughness mapping on controlled epoxy networks, POLYM ENG S, 39(2), 1999, pp. 385-392
Authors:
Messing, EM
Manola, J
Sarosdy, M
Wilding, G
Crawford, ED
Trump, D
Citation: Em. Messing et al., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N ENG J MED, 341(24), 1999, pp. 1781-1788
Authors:
Crawford, ED
Citation: Ed. Crawford, Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial - Comment, J UROL, 162(4), 1999, pp. 1351-1351
Authors:
Haas, GP
Blumenstein, BA
Gagliano, RG
Russell, CA
Rivkin, SE
Culkin, DJ
Wolf, M
Crawford, ED
Citation: Gp. Haas et al., Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study, J UROL, 161(6), 1999, pp. 1823-1825
Authors:
Ziada, AM
Crawford, ED
Citation: Am. Ziada et Ed. Crawford, Intravesical chemotherapy of bladder cancer, OX MED PUBL, 1999, pp. 327-343